DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Oxbryta is a drug marketed by Global Blood Theraps and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-one countries.
The generic ingredient in OXBRYTA is voxelotor. Additional details are available on the voxelotor profile page.
Oxbryta will be eligible for patent challenges on November 25, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 12, 2037. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Generic Entry Opportunity Date for OXBRYTA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Global Blood Theraps||OXBRYTA||voxelotor||TABLET;ORAL||213137-001||Nov 25, 2019||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Global Blood Theraps||OXBRYTA||voxelotor||TABLET;ORAL||213137-001||Nov 25, 2019||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Global Blood Theraps||OXBRYTA||voxelotor||TABLET;ORAL||213137-001||Nov 25, 2019||RX||Yes||Yes||Start Trial||Start Trial||Y||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|